Table 2 Change from baseline in lipoprotein and lipid levels after 6 weeks of treatment (ITT population)
Lipids/lipoproteins | Rosuvastatin 10 mg (n = 493) | Atorvastatin 20 mg (n = 481) | p value* | ||
|---|---|---|---|---|---|
Mean baseline level, mg/dL | LSM percentage change (SE) | Mean baseline level, mg/dL | LSM percentage change (SE) | ||
LDL-C | 165.1 | -44.6 (0.6) | 164.9 | -42.7 (0.6) | < 0.05 |
TC | 250.9 | -30.8 (0.5) | 250.9 | -30.7 (0.5) | ns |
HDL-C | 50.3 | 6.4 (0.5) | 49.9 | 3.1 (0.5) | < 0.001 |
TG | 178.1 | -17.9 (1.2) | 180.3 | -19.1 (1.2) | ns |
NonHDL-C | 200.6 | -40.1 (0.6) | 200.9 | -38.9 (0.6) | ns |
LDL-C/HDL-C | 3.5 | -47.6 (0.7) | 3.5 | -44.0 (0.7) | < 0.001 |
TC/HDL-C | 5.3 | -34.6 (0.5) | 5.3 | -32.3 (0.5) | < 0.01 |
NonHDL-C/HDL-C | 4.3 | -43.3 (0.6) | 4.3 | -40.2 (0.7) | < 0.001 |
Lp(a) | 32.6 | 2.1 (3.8) | 27.0 | 13.3 (3.8) | < 0.05 |
ApoB | 157.4 | -35.2 (0.6) | 156.6 | -34.1 (0.6) | ns |
ApoA-I | 160.5 | 4.8 (0.5) | 159.6 | 1.7 (0.5) | < 0.001 |
ApoB/ApoA-I | 1.0 | -37.6 (0.7) | 1.0 | -34.6 (0.7) | 0.001 |